{{Short description|Feline medication for arthritis}}
{{Use American English|date=January 2022}}
{{Use dmy dates|date=January 2022}}
{{Infobox drug
| drug_name         = 
| INN               = 
| type              = mab
| image             = 
| width             = 
| alt               = 
| caption           =

<!-- Monoclonal antibody data -->
| mab_type   = mab
| source     = a
| target     = [[Nerve growth factor]] (NGF)

<!-- Clinical data -->
| pronounce         = 
| tradename         = Solensia
| Drugs.com         = 
| MedlinePlus       = 
| licence_EU        = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID        = Frunevetmab
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_category= 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = [[Subcutaneous injection|Subcutaneous]]
| class             = 
| ATCvet            = yes
| ATC_prefix        = N02
| ATC_suffix        = BG90
| ATC_supplemental  =

<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  = 
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment  = 
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  = 
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  = 
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  = 
| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment  = 
| legal_US          = Rx-only
| legal_US_comment  = <ref>{{cite web | url=https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817 | title=NADA 141-546 Solensiaâ„¢ frunevetmab injection Injectable Solution Cats | publisher=animaldrugsatfda.fda.gov | archiveurl=https://web.archive.org/web/20220115030222/https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817 |archivedate=15 January 2022 }} {{Bare URL PDF|date=March 2022}}</ref><ref name="FDA PR 20220113" />
| legal_EU          = Rx-only
| legal_EU_comment  = <ref name="Solensia EPAR">{{cite web | title=Solensia EPAR | website=[[European Medicines Agency]] (EMA) | date=11 December 2020 | url=https://www.ema.europa.eu/en/medicines/veterinary/EPAR/solensia | access-date=14 January 2022 | archive-date=15 January 2022 | archive-url=https://web.archive.org/web/20220115040558/https://www.ema.europa.eu/en/medicines/veterinary/EPAR/solensia | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref>
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  = 
| legal_status      = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       = 
| onset             = 
| elimination_half-life = 
| duration_of_action = 
| excretion         =

<!-- Identifiers -->
| CAS_number_Ref    = 
| CAS_number        = 1708936-80-4
| CAS_supplemental  = 
| PubChem           = 
| IUPHAR_ligand     = 
| DrugBank_Ref      = 
| DrugBank          = 
| ChemSpiderID_Ref  = 
| ChemSpiderID      = 
| UNII_Ref          = 
| UNII              = 77O28MCS79
| KEGG_Ref          = 
| KEGG              = D10935
| ChEBI_Ref         = 
| ChEBI             = 
| ChEMBL_Ref        = 
| ChEMBL            = 
| NIAID_ChemDB      = 
| PDB_ligand        = 
| synonyms          =

<!-- Chemical and physical data -->
| IUPAC_name        = 
| chemical_formula_ref =
| chemical_formula  = 
| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I= 
| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge= 
| molecular_weight  = 
| molecular_weight_comment = 
| SMILES            = 
| StdInChI          = 
| StdInChI_comment  = 
| StdInChIKey       = 
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

'''Frunevetmab''', sold under the brand name '''Solensia''', is a [[medication]] used to treat pain associated with [[osteoarthritis]] in cats.<ref name="FDA PR 20220113">{{cite press release | title=FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species | website=U.S. [[Food and Drug Administration]] (FDA) | date=2022-01-13 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-control-pain-cats-osteoarthritis-first-monoclonal-antibody-drug-use-any | access-date=2022-01-14 | archive-date=2022-01-13 | archive-url=https://web.archive.org/web/20220113154907/https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-control-pain-cats-osteoarthritis-first-monoclonal-antibody-drug-use-any | url-status=live }} {{PD-notice}}</ref>

It is the first monoclonal antibody new animal drug approved by the U.S. [[Food and Drug Administration]] (FDA) for use in any animal species.<ref name="FDA PR 20220113" />

Frunevetmab is the [[international nonproprietary name]] (INN).<ref name=WHORecList78>{{cite journal | vauthors = ((World Health Organization)) | title = International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78 | journal = WHO Drug Information | volume = 31 | issue = 3 | year = 2017 | hdl = 10665/330961 | hdl-access = free | author-link = World Health Organization }}</ref>

== Clinical usage ==
Frunevetmab is a cat-specific [[monoclonal antibody]] (a type of protein) designed to recognize and attach to a protein called [[nerve growth factor]] (NGF) that is involved in the regulation of pain.<ref name="FDA PR 20220113" /> When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.<ref name="FDA PR 20220113" />

Frunevetmab is [[Indication (medicine)|indicated]] for the alleviation of pain associated with osteoarthritis in cats.<ref name="FDA PR 20220113" /><ref name="Solensia EPAR" />

The most common side effects seen in cats include [[vomiting]], [[diarrhea]], injection site pain, scabbing on the head and neck, [[dermatitis]], and [[pruritus]] (itchy skin).<ref name="FDA PR 20220113" />

==History==
In February 2021, Frunevetmab was approved for medical use in the European Union.<ref name="Solensia EPAR" />

In January 2022, the following year, Frunevetmab was approved for medical use in the United States.<ref name="FDA PR 20220113" /><ref>{{cite web | title=Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats | publisher=Zoetis | date=2022-01-13 | url=https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-FDA-Approval-of-Solensia-frunevetmab-injection-to-Control-Osteoarthritis-Pain-in-Cats/default.aspx | access-date=2022-01-14 | archive-date=2022-01-13 | archive-url=https://web.archive.org/web/20220113235612/https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-FDA-Approval-of-Solensia-frunevetmab-injection-to-Control-Osteoarthritis-Pain-in-Cats/default.aspx | url-status=live }}</ref>

Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. <ref>{{cite web |url=https://www.painnewsnetwork.org/stories/2022/1/14/fda-approves-pain-reliever-for-cats-considered-too-risky-for-humans}}</ref>

==See also==
*[[Monoclonal antibody]]

== References ==
{{reflist|1}}
{{HHS content|url=https://www.fda.gov/}}

== Bibliography ==
* {{cite journal | vauthors = Gruen ME, Myers JA, Lascelles BD | title = Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study | journal = Frontiers in Veterinary Science | volume = 8 | issue =  | pages = 610028 | date = 2021 | pmid = 34124212 | pmc = 8195238 | doi = 10.3389/fvets.2021.610028 | title-link = doi | doi-access = free }}

== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/frunevetmab | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Frunevetmab }}

{{Analgesics}}
{{Portal bar | Medicine}}

[[Category:Monoclonal antibodies]]
[[Category:Cat medications]]


{{veterinary-med-stub}}